Catalyst Capital Advisors LLC Tcr2 Therapeutics Inc. Transaction History

Catalyst Capital Advisors LLC

  • $4.41 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 05, 2019
SELL
$10.15 - $19.53 $4,658 - $8,964
-459 Closed
0 $0
Q1 2019

May 08, 2019
BUY
$15.01 - $22.15 $6,889 - $10,166
459 New
459 $8,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Catalyst Capital Advisors LLC Portfolio

Follow Catalyst Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Capital Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email